Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Dec. 2025, Nuveen Multi-Marketome Fund has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Nuveen Multi-Marketome Fund (NYSE:JMM) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2025, Nuveen Multi-Marketome Fund has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Nuveen Multi-Marketome Fund Sloan Ratio % Related Terms
Nuveen Multi-Marketome Fund Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, Nuveen Multi-Marketome Fund's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuveen Multi-Marketome Fund Sloan Ratio % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Nuveen Multi-Marketome Fund's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Nuveen Multi-Marketome Fund's Sloan Ratio % falls into.
Nuveen Multi-Marketome Fund Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data.
Nuveen Multi-Marketome Fund's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was 2.825 (Jun. 2025 ) + 1.96 (Dec. 2025 ) = $4.79 Mil.
Nuveen Multi-Marketome Fund's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was -0.258 (Jun. 2025 ) + 1.29 (Dec. 2025 ) = $1.03 Mil.
Nuveen Multi-Marketome Fund's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2025 was 0 (Jun. 2025 ) + 0 (Dec. 2025 ) = $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuveen Multi-Marketome Fund (JMM) has a Sloan Ratio % of 0.00% as of Dec. 2025. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Nuveen Multi-Marketome Fund and its competitors.
Is Nuveen Multi-Marketome Fund's Sloan Ratio % too high?
Nuveen Multi-Marketome Fund's current Sloan Ratio % is 0.00%. Overall, Nuveen Multi-Marketome Fund has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nuveen Multi-Marketome Fund's Sloan Ratio % compare to MXE and BENF?
Nuveen Multi-Marketome Fund's Sloan Ratio % of 0.00% can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for an Asset Management company?
A good Sloan Ratio % depends on the Asset Management industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Nuveen Multi-Marketome Fund and its competitors. Nuveen Multi-Marketome Fund's current Sloan Ratio % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuveen Multi-Marketome Fund stock overvalued right now?
Based on GuruFocus' analysis, Nuveen Multi-Marketome Fund (JMM) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.55, compared to a current price of $5.77 — trading 23.6% below its estimated fair value. The current Sloan Ratio % is 0.00%. Nuveen Multi-Marketome Fund's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Nuveen Multi-Marketome Fund (JMM), the current Sloan Ratio % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nuveen Multi-Marketome Fund (JMM) Overvalued in 2026?
Based on GuruFocus' analysis, Nuveen Multi-Marketome Fund stock appears to be undervalued.
The current stock price of $5.77 is trading 23.6% below its estimated GF Value™ of $7.55.
GuruFocus considers Nuveen Multi-Marketome Fund to be Modestly Undervalued.
Key valuation signals for JMM:
Sloan Ratio %: 0.00%
GF Value™: $7.55 vs. price of $5.77 (23.6% below fair value)
No single metric tells the full story. See the JMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
48GF Score
Get the complete analysis for JMM
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JMM has been successfully added to your 
